The company’s stock price has collected 21.29% of gains in the last five trading sessions. Every investor on earth makes bad calls sometimes. OVID--0.00%--Global Fragile X Syndrome Market impact of COVID-19 on Share, Size 2021 Movements by Growth Status, Trend Analysis, Revenue Expectation to 2025 Research Report by Research Reports World. The market is probably reacting to Ovid getting a buy rating from an analyst. Find real-time OVID - Ovid Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Get Ovid Therapeutics, Inc.'s stock price today. Ovid Therapeutics Inc NASDAQ Updated Feb 16, 2021 8:59 PM. Ovid Therapeutics Inc () Stock Market info Recommendations: Buy or sell Ovid Therapeutics stock? Shares of Ovid Therapeutics (NASDAQ: OVID) -- a clinical-stage biotech company -- are down by 55% as of 11:04 a.m. EST on Wednesday, after falling by as much as 56.4% earlier in the day. Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) have been assigned a consensus rating of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Why Ovid Therapeutics Stock Is Imploding Today. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Ovid Therapeutics against related stocks people have also bought. The stock has traded between $2.62 and $2.79 so far today. HOME MARKET TRADE PRICING DOWNLOAD HELP. The post Ovid Therapeutics News: Why OVID Stock … Seeking Alpha 72d. Ovid Therapeutics Inc. (NASDAQ:OVID) went up by 11.44% from its latest closing price compared to the recent 1-year high of $9.40. Get the latest Ovid Therapeutics Inc. (OVID) stock news and headlines to help you in your trading and investment decisions. Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today InvestorPlace Dec 02, 2020 Ovid Therapeutics misses goal in Angelman syndrome treatment Seeking Alpha Dec 01, 2020 If we look at who the major shareholders are, we find that insiders hold 34.69% of Ovid Therapeutics Inc. shares while 39.8% of the shares are in the hands of institutional holders. That doesn't bode well for Ovid Therapeutics, and it explains why shares of the biotech company-- which has no drugs on the market at the moment -- are getting clobbered on the stock … Ovid Therapeutics Stock News module provides quick insight into current market opportunitiescurrent market opportunities View OVID THERAPEUTC OVID investment & stock information. Latest OVID News From Around the Web Considering analysts have assigned the stock a price target range of $4-$16 as the low and high respectively, we find the trailing 12-month average consensus price target to be $8. The share float percentage for the stock … OVID 3.73 0.31 (9.06%). As of this writing, more than 8 million shares of OVID stock have changed hands. Over the past 1 days, the trend for OVID's stories per day has been choppy and unclear. View the real-time OVID price chart on Robinhood and decide if you want to buy or sell commission-free. To see InvestorsObserver's Sentiment Score for Ovid Therapeutics Inc click here. Ovid Therapeutics Inc. (NASDAQ:OVID)’s Major holders. Ovid Therapeutics Inc. closed the trading session at $2.93 on 12/02/20. Ovid Therapeutics is seeing heavy trading following the bad news. OVID stock quote, chart and news. Ovid Therapeutics Inc. analyst estimates, including OVID earnings per share estimates and analyst recommendations. It has oscillated between 1 and 1. Shares of Ovid Therapeutics were up by 29.1%, despite the company not reporting any news. The average twelve-month price objective among brokers that […] So consider, for a moment, the misfortune of Ovid Therapeutics Inc. (NASDAQ:OVID) investors who have held the stock for three years as it declined a whopping 73%.That would be a disturbing experience. The company’s stock price has collected -2.00% of loss in the last five trading sessions. Ovid Therapeutics Inc. (NASDAQ:OVID) went down by -7.80% from its latest closing price compared to the recent 1-year high of $9.40. Webull offers OVID stock news, real time Ovid news help you invest smart. Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today. your username. News. InvestorPlace 72d. LOG IN. ----- Michael Higgins, an analyst with Ladenburg Thalmann, reiterated a buy rating on Ovid's stock today. For OVID, its 30 day story count is now at 2. Why Ovid Therapeutics Stock Is Imploding Today. OVID News Highlights. Ovid has a broad pipeline of potential first-in-class medicines. So far 1,892,433 shares have traded compared to average volume of 1,470,621 shares. Find the latest news headlines from Ovid Therapeutics Inc. Common Stock (OVID) at Nasdaq.com. A rank of 37 means that 63% of stocks appear more favorable to our system. CPE, FCEL, MACK and WKHS among midday movers. Press Release reported on 11/12/20 that Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Ovid Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. We use our internally-built news screening methodology to estimate the value of Ovid Therapeutics based on different types of headlines from major news … your password Click here now. The Investor Relations website contains information about Ovid Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. Real time Ovid Therapeutics Inc. (OVID) stock price quote, stock graph, news & analysis. Find the latest Ovid Therapeutics Inc. (OVID) stock quote, history, news and other vital information to help you with your stock trading and investing. But you have a problem if you face massive losses more than once in a while. Log into your account. SIGN UP. Welcome! Stock analysis for Ovid therapeutics Inc (OVID:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. In comparing Ovid Therapeutics Inc. (OVID)’s stock with other industry players reveals that stock’s current price change of 0% and that of -11.84% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 0.76% in the last trading and went through an increase of 4.15% in past 12-month trading. What this means: InvestorsObserver gives Ovid Therapeutics Inc (OVID) an overall rank of 37, which is below average. Get the hottest stocks to trade every day before the market opens 100% free. Press Release reported on 12/01/20 that Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet … Ovid Therapeutics Inc. (NASDAQ:OVID) price on Friday, Feb 19, dropped -7.8% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.43. Ovid Therapeutics Inc. Common Stock (OVID) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. 5,920 Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of an underwritten offering of 6,250,000 shares of its common stock. Get the latest OVID THERAPEUTC OVID detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Volume today is more active than usual. Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid Therapeutics Inc. (NASDAQ:OVID)’s beta value is holding at 1.86, while the average true range (ATR) indicator is currently reading 0.16. It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal.